Annexon Reiterates Q4 2026 Readout for GA Trial, No New Data

What happened

Annexon confirmed it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy during Q4 2026, with vision preservation as the primary efficacy focus. This timeline is consistent with prior company guidance and the existing master report, adding specificity but offering no new clinical data. The trial is designed to show prevention of ≥15-letter BCVA loss, a more clinically meaningful but higher-risk endpoint than lesion growth used by competitors. With cash runway into late Q1 2027, the company is positioned to reach this readout without immediate financing pressure, but the event remains a binary catalyst more than a year away.

Implication

In the near term, investors should prioritize regulatory milestones for tanruprubart in Guillain-Barré syndrome, as that remains the primary value driver. The GA readout is over a year out and should not dominate short-term valuations. A positive outcome would diversify revenue potential and validate the anti-C1q platform in ophthalmology, but the vision preservation endpoint is unproven and carries meaningful risk. Failure would likely trigger a re-rating as the GA program loses value, increasing financing risk despite the current cash buffer. Overall, maintain a cautious stance on GA until data is available.

Thesis delta

No shift in thesis; the news reiterates existing guidance with added specificity on timing and endpoint. The ARCHER II readout remains a key catalyst for H2 2026, but the primary near-term value driver continues to be regulatory progress for tanruprubart in GBS.